BIO Asia–Taiwan 2025 亞洲生技大會

Unlocking the Future of Brain Health

This high-impact special session brings together renowned medical leaders, cutting-edge biotech innovators, and government policy makers to present the most up-to-date insights and technologies in the fight against dementia. Come to network with leading scientists, clinicians, and biotech CEOs from Taiwan, Japan, and Korea.

 Session Highlights Include:

• Opening Remarks – Jen-Der Lue, Deputy Minister, Ministry of Health and Welfare

• Keynote Speech – Shih-Chia Lin, CEO, Foundation of Medical Professionals Alliance in Taiwan (FMPAT)

• National Policy Update – Ministry of Health and Welfare 

• Clinical & Research Insights – Taiwan Dementia Society, QST Japan, Novascope Diagnostics, APRINOIA Therapeutics, and more 

In Session 1: Innovations in Diagnostics will spotlight From next-gen diagnostic platforms and molecular imaging probes to advanced PET acquisition and blood-based biomarker technology, this session explores the future of Alzheimer’s detection. Featured speakers include Dr. Ming-Kuei Jang, CEO of APRINOIA Therapeutics and APN LifeSciences; Dr. Makoto Higuchi, Director of the Advanced Neuroimaging Center at QST Japan and Professor at Osaka Metropolitan University; Dr. Taiga Yamaya, Group Leader of Imaging Physics and Deputy Director at QST’s Department of Advanced Nuclear Medicine Sciences; and Dr. Lu-Yi Lu, CEO of Novascope Diagnostics.

And Session 2: Breakthrough Treatments for Alzheimer’s Disease will spotlight From immunotherapy and protein degraders to astrocyte-mediated clearance and neuroinflammation suppression, this session delves into next-generation therapeutic strategies for Alzheimer’s Disease. Featured speakers include Dr. Ming-Kuei Jang, CEO of APRINOIA Therapeutics and APN LifeSciences; Dr. Sanghoon Park, CEO of Illimis Therapeutics; and Dr. Hung-Kai Kevin Chen, CEO of Elixiron Immunotherapeutics.

Seats are limited — reserve yours now!

Early Bird: Register by 6/20 & Save $275